| 郭明升,郭英杰,刘娟,等.脑梗死二级预防联用阿托伐他汀和强肝胶囊降脂及安全性析因分析[J].安徽医药,2020,24(1):9-12. |
| 脑梗死二级预防联用阿托伐他汀和强肝胶囊降脂及安全性析因分析 |
| Factorial analysis of lipid?lowering effect and safety of combined atorvastatin with Qianggan capsule in patients with cerebral infarction secondary preventiona |
| |
| DOI：10.3969/j.issn.1009?6469.2020.01.003 |
| 中文关键词: 脑梗死 二级预防 降血脂药物 三酰甘油类 胆固醇酯类 胆固醇， HDL 阿托伐他汀 强肝胶囊 析因分析 |
| 英文关键词: Brain infarction Secondary prevention Hypolipidemic agents Triglycerides Cholesterol esters Cholesterol,HDL Atorvastatin Qianggan capsule Factorial analysis |
| 基金项目:河北省医学科学研究重点课题计划( 20181744)；邯郸市科学技术研究与发展计划项目( 1823208019ZC) |
|
| 摘要点击次数: 2253 |
| 全文下载次数: 602 |
| 中文摘要: |
| 目的评估动脉粥样硬化性脑梗死( ACI)二级预防病人联用不同剂量阿托伐他汀和强肝胶囊的降脂效果及其安全性。方法选择 2017年 8月至 2018年 1月于冀中能源峰峰集团有限公司总医院神经内科住院的急性脑梗死病人 180例，病因分型为 TOAST大动脉粥样硬化型或小动脉闭塞型，合并高脂血症，既往无类似发作。入选病人按随机数字表法分为 10 mg对照组、 20 mg对照组、 40 mg对照组和 10 mg观察组、 20 mg观察组、 40 mg观察组，均给予对应剂量的阿托伐他汀钙片，口服，每晚 1次；观察组额外加用强肝胶囊 2g，口服，每天 2次；疗程均为 3个月。测定治疗前后病人血脂［三酰甘油( TG)、总胆固醇( TC)、低密度脂蛋白胆固醇( LDL?C)］和谷丙转氨酶( ALT)数值。析因分析比较用药种类、阿托伐他汀剂量对上述指标的影响。结果治疗后阿托伐他汀相同剂量组间比较: 20 mg观察组 TC水平显著低于 20 mg对照组［( 4.04±0.77)比( 4.69±0.91)mmol/L，P＜ 0.01］，差异有统计学意义。关于 LDL?C和 ALT水平， 10 mg观察组显著低于 10 mg对照组［(2.98±0.49)比( 3.34±0.42)mmol/L、 |
| 英文摘要: |
| Objective To evaluate the lipid?lowering effect and safety of different doses of atorvastatin combined with Qianggan capsule in patients with secondary prevention of atherosclerotic cerebral infarction(ACI).Methods From August 2017 to January2018, 180 patients with acute cerebral infarction who were hospitalized in neurology department of General Hospital of Jizhong En?ergy Fengfeng Group Co., Ltd. were selected. The etiology was classified as toast big atherosclerosis type or small artery occlusiontype, with hyperlipidemia and no similar attack in the past.All patients were divided by random digital table method into 10 mgcontrol group，20 mg control group，40 mg control group，10 mg observation group，20 mg observation group and 40 mg observation group and were treated with the corresponding dose of atorvastatin calcium tablets，oral，once a night，and patients in three obser? vation groups were additive treated with 2 g Qianggan capsule，orally，twice a day for 3 months.Levels of serum lipids［Triglycer? ide(TG)Total cholesterol(TC)，low density lipoprotein cholesterol(LDL?C)］ and alanine aminotransferase(ALT)were mea? suredbefore，and after treatment.Effects of drug types and atorvastatin dose on the above indexes were analyzed by factorial analy?sis.Results TC level in 20 mg observation group was significantly lower than that in 20 mg control group［( 4.04±0.77)vs.(4.69± 0.91)mmol/L，P＜0.01］.The levels of LDL?C and ALT in 10 mg observation group were significantly lower than those in 10 mg control group［( 2.98±0.49)vs.(3.34±0.420 mmol/L，(21.6±4.3)vs.(29.1±6.3)U/L，P＜0.05］，while those in 20 mg observation group was significantly lower than those in 20 mg control group［(2.66±0.45)vs.(2.95±0.42)mmol/L，(25.2±4.6)vs.(32.4±6.1)U/ L，P＜0.05］，and these in 40 mg observation group was significantly lower than these in 40 mg control group［( 2.41±0.48)vs. (2.70±0.47)mmol/L，(31.8±6.2)vs.(36.1±6.4)U/L，P＜0.05］.The factorial analysis results showed that combination atorvastatin with Qianggan capsule had significant influence on the changes of TC，LDL?C and ALT(P＜0.01).Conclusion Atorvastatin com? bined with Qianggan capsule improves the lipid?lowering effect and safety in patients with ACI secondary prevention. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
